The main risk is sequencing, not survival. IonQ has cash, strategic relevance, and a stronger control position after
SkyWater, but the equity still requires timely proof that
Superion can be manufactured, delivered, and used in ways that create durable recurring revenue before the market stops paying frontier-compute multiples.